Table 7. Pros and cons of available intrathecal agents.
Ziconotide | Opioid | |
---|---|---|
Death from Overdose | no | yes |
Withdrawal Symptoms if abrupt cessation | no | yes |
Need for planned 23 hour observation following trial and implant | no (if no neurologic signs or symptoms post 8 hours from dosing) | yes |
Need for accurate dosing | yes | yes |
Granulomagenic | no | yes* |
*fentanyl may not be granulomagenic.